Nature Communications (Sep 2016)
Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
Abstract
High-affinity IL-2Rα expressed by Tregs mitigates the potential of IL-2 use in cancer therapy. Here, the authors fuse IL-2 with an NKDG2 binding domain, and show that it induces IL-2 signalling selectively in NKG2D+cells, delaying tumour growth in mice without the side effects of conventional IL-2 therapy.